NeoStem Set to Join Multiple Russell Indexes
June 23 2014 - 7:30AM
NeoStem, Inc. (Nasdaq:NBS), a leader in the emerging cellular
therapy industry, announced today that it is set to join the
broad-market Russell Global, Russell 3000, and Russell Microcap
Indexes when Russell Investments reconstitutes its comprehensive
set of U.S. and global equity indexes on Friday, June 27, 2014,
according to a preliminary list of additions posted June 13 on
www.russell.com/indexes.
"We are very pleased that NeoStem's opportunistic growth
strategy, demonstrated through our recent acquisition of California
Stem Cell, Inc. (now known as NeoStem Oncology, LLC) and its
Targeted Immunotherapy Program, has contributed to the Company's
anticipated inclusion in the Russell Global, Russell 3000, and
Russell Microcap Indexes," said Dr. Robin L. Smith, Chairman and
CEO of NeoStem. "We hope that our inclusion in these indexes will
increase awareness among investors of NeoStem and our unique
platform that includes cell therapy development as well as revenue
generating manufacturing capabilities that we are able to leverage
both for our clients and our own clinical programs with anticipated
near-term milestones."
Annual reconstitution of Russell's U.S. indexes captures the
4,000 largest U.S. stocks as of the end of May, ranking them by
total market capitalization. The Russell Global Index, which
captures approximately 98% of investable securities globally, is
reconstituted annually and all sub-indexes are recalibrated
simultaneously to accurately measure current market realities for
each market segment. Membership in these indexes, which remains in
place for one year, means automatic inclusion in the small-cap
Russell 2000® Index as well as the appropriate growth and value
style indexes, as well as the applicable sector and country
indexes. Russell determines membership for its equity indexes
primarily by objective, market-capitalization rankings and style
attributes.
Russell indexes are widely used by investment managers and
institutional investors for index funds and as benchmarks for
active investment strategies. Approximately $5.2 trillion in assets
are benchmarked to the Russell Indexes. Russell calculates more
than 700,000 benchmarks daily covering approximately 98 percent of
the investable market globally, more than 80 countries and 10,000
securities. These investment tools originated from Russell's
multi-manager investment business in the early 1980s when the
company saw the need for a more objective, market-driven set of
benchmarks in order to evaluate outside investment managers.
Total returns data for the Russell 3000 and other Russell
Indexes is available
at http://www.russell.com/indexes/americas/indexes/daily-returns.page.
About Russell
Russell Investments (Russell) is a global asset manager and one
of only a few firms that offers actively managed multi-asset
portfolios and services that include advice, investments and
implementation. Russell stands with institutional investors,
financial advisors and individuals working with their
advisors—using the firm's core capabilities that extend across
capital market insights, manager research, portfolio construction,
portfolio implementation and indexes to help each achieve their
desired investment outcomes.
Russell has more than $259 billion in assets under management
(as of 3/31/2014) and works with over 2,500 institutional clients,
independent distribution partners and individual investors
globally. As a consultant to some of the largest pools of capital
in the world, Russell has $2.4 trillion in assets under advisement
(as of 6/30/2013). It has four decades of experience researching
and selecting investment managers and meets annually with more than
2,200 managers around the world. Russell traded more than $1.6
trillion in 2013 through its implementation services business.
Russell also calculates approximately 700,000 benchmarks daily
covering 98% of the investable market globally, including more than
80 countries and more than 10,000 securities. Approximately $5.2
trillion in assets are benchmarked (as of 12/31/2013) to the
Russell Indexes, which have provided investors with 30 years of
smarter beta.
About NeoStem, Inc.
NeoStem is a leader in the emerging cellular therapy industry,
pursuing the preservation and enhancement of human health globally
through the development of cell based therapeutics that prevent,
treat or cure disease by repairing and replacing damaged or aged
tissue, cells and organs and restoring their normal function. The
business includes the development of novel proprietary cell therapy
products as well as a revenue-generating contract development and
manufacturing service business. This combination has created an
organization with unique capabilities for cost effective in-house
product development and immediate revenue and cash flow generation.
www.neostem.com
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements reflect management's current
expectations, as of the date of this press release, and involve
certain risks and uncertainties. Forward-looking statements include
statements herein with respect to the successful execution of the
Company's business strategy, the Company's ability to develop and
grow its business, the successful development of cellular therapies
with respect to the Company's research and development and clinical
evaluation efforts in connection with the Company's Targeted
Immunotherapy Program, CD34 Cell Program, T Regulatory Cell Program
and other cell therapies, the future of the regenerative medicine
industry and the role of stem cells and cellular therapy in that
industry, the performance and planned expansion of the Company's
contract development and manufacturing business and the Company's
final and continued inclusion on any Russell indexes. The Company's
actual results could differ materially from those anticipated in
these forward-looking statements as a result of various factors.
Factors that could cause future results to materially differ from
the recent results or those projected in forward-looking statements
include the "Risk Factors" described in the Company's Annual Report
on Form 10-K filed with the Securities and Exchange Commission
("SEC") on March 13, 2014, the Company's Current Report on Form 8-K
filed with the SEC on May 8, 2014 and in the Company's other
periodic filings with the SEC. The Company's further development is
highly dependent on future medical and research developments and
market acceptance, which is outside its control.
CONTACT: Investor Contact:
LifeSci Advisors, LLC
Michael Rice
Founding Partner
Phone: +1-646-597-6979
Email: mrice@lifesciadvisors.com
Media Contact:
NeoStem, Inc.
Eric Powers
Manager of Communications and Marketing
Phone: +1-212-584-4173
Email: epowers@neostem.com
NeoStem, Inc. (NASDAQ:NBS)
Historical Stock Chart
From Jun 2024 to Jul 2024
NeoStem, Inc. (NASDAQ:NBS)
Historical Stock Chart
From Jul 2023 to Jul 2024